Building an Academic Program in Developmental Therapeutics
Frontiers in Oncology Seminar Series
Tuesday, August 4, 2020
8:00 – 9:00 AM
Geoffrey Shapiro, MD, PhD
Dr. Geoffrey Shapiro currently serves as the Senior Vice President of Developmental Therapeutics at the Dana-Farber Cancer Institute. Over the past decade, he was the Director of Dana-Farber’s Early Drug Development Center, where he led early phase clinical trials of many anticancer agents including inhibitors of signal transduction, cell cycle, DNA repair, cellular transcription and immune checkpoints, many of which have gone on to FDA approval. He is also the Clinical Director for the DFCI Center for DNA Damage and Repair and is developing multiple PARP and ATR inhibitor combinations tied to Breast, Ovarian and GI SPORE grants. Dr. Shapiro leads Dana-Farber/ Harvard Cancer Center efforts within the National Cancer Institute (NCI) Experimental Therapeutics Clinical Trials Network (ETCTN) and was recently elected as co-Chair of the NCI Investigational Drug Steering Committee, a national advisory council for early anti-cancer drug development.